Warner Carr, MD
Allergy · Laguna Niguel, CANPI 1184798001
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 50 manufacturers reported payments, led by AstraZeneca at 38.9% of the total. Among allergy clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 952 payments — averaging $599.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$222K
- Regeneron Healthcare Solutions, Inc.$71K
- Merz North America, Inc.$69K
- Sanofi$32K
- Sanofi-aventis U.S. LLC$31K
- ARS Pharmaceuticals Operations, Inc.$27K
- plus $118K from 44 others
Across 484 payments — averaging $3785.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$719K
- Aimmune Therapeutics, Inc.$234K
- GSK$128K
- Astrazeneca UK Limited$107K
- AstraZeneca$104K
- Novartis$103K
- plus $436K from 13 others
What the payments were for
- Consulting fees$274,78448%
- Speaking & faculty fees$225,01639%
- Travel & lodging$46,6688%
- Food & beverage$24,4174%
- Education$900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$570,975 in reported general payments places this provider in the 95th percentile of 117 allergy providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TezspireTezepelumab-Ekko | 73 | $320,576 |
| Dupixent SyringeDupilumab | 38 | $150,217 |
| Dupixent PenDupilumab | 15 | $86,064 |
| XolairOmalizumab | 23 | $84,128 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $58,776 |
| Spiriva RespimatTiotropium Bromide | 68 | $53,977 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $33,043 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $14,904 |
| SymbicortBudesonide/Formoterol Fumarate | 46 | $14,395 |
| XhanceFluticasone Propionate | 13 | $10,821 |
| BreynaBudesonide/Formoterol Fumarate | 44 | $9,650 |
| Qvar RedihalerBeclomethasone Dipropionate | 21 | $8,424 |
| DuleraMometasone/Formoterol | 11 | $6,574 |
| Ipratropium Bromide | 172 | $6,328 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $5,802 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $222,032 | $368,014166 claims |
| Genentech, Inc.Xolair | $104 | $84,12823 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $879 | $73,68098 claims |
| Boehringer IngelheimSpiriva Respimat | $74 | $53,97768 claims |
| Optinose US, Inc.Xhance | $9,495 | $10,82113 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $15,799 | $8,42421 claims |
| MerckDulera | $15,213 | $6,57411 claims |
| Hikma Pharmaceuticals USAEpinephrine | $6,965 | $2,77916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 117 allergy providers in California.
Other allergy in Laguna Niguel
- Christine Lee-KimLaguna Niguel$7K
- Mark SugarLaguna Niguel$3K
- Joshua JacobsWalnut Creek$1.5M
- Bradley ChippsSacramento$571K
- Travis MillerRoseville$273K
- Robert ZeigerSan Diego$162K
- William BergerMission Viejo$76K
- Sandra ChristiansenSan Diego$74K
- Stephen WongHacienda Heights$50K
- Michelle YasharpourBeverly Hills$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.